Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albuterol spiromax
- Development stage
- Approved
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation
01
Overview
Albuterol Spiromax is a branded formulation of albuterol (also known as salbutamol) delivered via the Spiromax dry powder inhaler device. Albuterol is a short-acting beta-2 adrenergic receptor agonist (SABA) used primarily for the prevention and treatment of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing smooth muscle in the airways, leading to bronchodilation and improved airflow. The drug provides rapid relief from acute symptoms like wheezing, shortness of breath, chest tightness, and coughing. The primary indication for Albuterol Spiromax is the management of reversible obstructive airway diseases[1][7].
- Brand names
- Albuterol Spiromax
- Other names
- albuterol inhalation aerosolsalbutamol (international name)
02
Targets
ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on albuterol spiromax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albuterol spiromax.